Mersana Therapeutics
Mersana Therapeutics
MRSN
NASDAQ
0.51
USD
0.00%
About
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen.
Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells.
The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 909.2K |
| Three Month Average Volume | 28.5M |
| High Low | |
| Fifty-Two Week High | 6.2801 USD |
| Fifty-Two Week Low | 1.065 USD |
| Fifty-Two Week High Date | 11 Mar 2024 |
| Fifty-Two Week Low Date | 31 Oct 2023 |
| Price and Volume | |
| Current Price | 1.58 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -7.11% |
| Thirteen Week Relative Price Change | -36.64% |
| Twenty-Six Week Relative Price Change | -75.81% |
| Fifty-Two Week Relative Price Change | 13.60% |
| Year-to-Date Relative Price Change | -42.49% |
| Price Change | |
| One Day Price Change | 3.95% |
| Thirteen Week Price Change | -32.19% |
| Twenty-Six Week Price Change | -73.40% |
| Five Day Price Change | 1.28% |
| Fifty-Two Week Price Change | 42.34% |
| Year-to-Date Price Change | -31.90% |
| Month-to-Date Price Change | -21.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.30572 USD |
| Book Value Per Share (Most Recent Quarter) | 0.06869 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.30572 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.06869 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.83629 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.31741 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.24688 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.47847 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.8648 USD |
| Normalized (Last Fiscal Year) | -1.40344 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.47847 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.8648 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.47847 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.8648 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.73209 USD |
| Cash Per Share (Most Recent Quarter) | 1.32661 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.46541 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.85001 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.10129 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -476 |
| Cash Flow Revenue (Trailing Twelve Months) | -446 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -349.98% |
| Pretax Margin (Last Fiscal Year) | -465.80% |
| Pretax Margin (5 Year) | -622.19% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -487.51% |
| Operating Margin (Trailing Twelve Months) | -373.53% |
| Operating Margin (5 Year) | -630.09% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -465.80% |
| Net Profit Margin (Trailing Twelve Months) | -349.98% |
| Net Profit Margin (5 Year) | -622.19% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -4.18% |
| Tangible Book Value (5 Year) | 33.22% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -78.48% |
| Revenue Growth (3 Year) | 28.32% |
| Revenue Change (Trailing Twelve Months) | -22.68% |
| Revenue Per Share Growth | -7.15% |
| Revenue Growth (5 Year) | 254.40% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 9.61% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 57.81% |
| EPS Change (Trailing Twelve Months) | 57.80% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 23 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -137,360,000 |
| Net Debt (Last Fiscal Year) | -183,655,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 6 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 23 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 63 |
| Long Term Debt to Equity (Most Recent Quarter) | 202 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -171,050,000 |
| Free Cash Flow (Trailing Twelve Months) | -133,545,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 69 |
| Total Debt to Equity (Most Recent Quarter) | 301 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -61.27% |
| Return on Assets (Trailing Twelve Months) | -42.75% |
| Return on Assets (5 Year) | -61.68% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -266.24% |
| Return on Equity (Trailing Twelve Months) | -213.33% |
| Return on Equity (5 Year) | -121.94% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -84.73% |
| Return on Investment (Trailing Twelve Months) | -59.36% |
| Return on Investment (5 Year) | -81.35% |